KTN's online platform helps you to make the connections you need

 

The Knowledge Transfer Network (KTN) has refreshed its online platform to intelligently connect you to relevant events, funding, thought pieces and specialist staff to help your business innovate and grow.

You can discover content using your area of interest, from Defence Security to transport; from space to health – all major UK economic sectors are covered. Once you have selected your interests, using our intelligent tagging system, we will then display rich and relevant content related to your area, often from surprising sources.

An example might be new satellite technology from the space sector that is applicable in the agri-food sector. KTN-UK.co.uk will help you form these unusual and valuable connections.

All content on the platform has been carefully curated by our team of innovation specialists – not by an automated algorithm – so you can be confident that KTN is connecting you to the most relevant cutting-edge information.

 

The move also marks a closer alignment with our main funder, Innovate UK , with the website branding making a clear visual link. Knowledge Transfer Network is Innovate UK's innovation network partner, and also works with other funders to provide innovation networking services and fulfil our mission to drive UK growth.

We link new ideas and opportunities with expertise, markets and finance through our network of businesses, universities, funders and investors. From agri-food to autonomous systems and from energy to design, KTN combines expertise in all sectors with the ability to cross boundaries. Connecting with KTN can lead to potential partners, horizon-expanding events and innovation insights relevant to your needs.

Visit our people pages to connect directly with expertise in your sector.

Visit the KTN refreshed online platfom here

Entries with tag vaccines .

£22m investment in Liverpool by global biopharma company

World's second biggest influenza vaccine manufacturer expands operations at Speke site The world's no. 2 influenza vaccine provider, Seqirus, announced a £22.1m investment for its UK manufacturing site in Liverpool. The company, which is part of global biotherapeutics leader CSL Limited, is going to develop a new £15.3m manufacturing facility to support the production of influenza...
Read More About £22m investment in Liverpool by global biopharma company »

New vaccines for globalepidemics: developmentand manufacture Competition for development contracts

The Department of Health is to invest up to £10 million in two competition streams in line with the priorities identified by the UK Vaccine Network. This SBRI competition aims to stimulate the development of: vaccine for priority infectious diseases vaccine platform technology manufacturing technologies that would allow for the rapid manufacture of vaccines in low-income...
Read More About New vaccines for globalepidemics: developmentand manufacture Competition for development contracts »

New vaccines for global epidemics: development and manufacture

The Department of Health is to invest up to £10 million in two competition streams in line with the priorities identified by the UK Vaccine Network. Vaccines are among the most cost-effective medical countermeasure for confronting epidemics or pandemics. Their effectiveness in preventing disease outbreaks has been far-reaching, and their availability could significantly reduce...
Read More About New vaccines for global epidemics: development and manufacture »

Midatech signs licencing agreement with Emergex Vaccines

Midatech Pharma, the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, have announced that the Company has entered into a licensing agreement with Emergex Vaccines Limited (“Emergex”), a private UK biotechnology company focused on infectious diseases utilising Midatech’s gold nanoparticle technology....
Read More About Midatech signs licencing agreement with Emergex Vaccines »

£250,000 investment for vaccine research firm

A bio firm, which discovers and develops vaccines to prevent bacterial infections, has received a £250,000 funding boost. Absynth Biologics received the investment from Alderley Park Ventures, the £5m investment fund created in late 2014 and managed by BioCity, to invest in life science companies based at BioHub on the Alderley Park site in Cheshire. Absynth Biologics, a University...
Read More About £250,000 investment for vaccine research firm »

Highlight notice in novel tools and technologies for vaccinology

Call status: Open Expression of interest deadline: 17 September 2015, 4pm Background Vaccine research to: develop tools and technologies for vaccine development identify new antigens for specific diseases take new vaccines through all stages of clinical development for human disease, and up to pre-clinical for animal diseases forms a key part of...
Read More About Highlight notice in novel tools and technologies for vaccinology »

Medical Research Council (MRC) – Leading science for better health

The MRC has committed £5m towards a new UK Research and Development Vaccines Network, which will bring together the UK’s leaders in drug development and research, to focus on the most serious global health threats. To read the article, please click here .
Read More About Medical Research Council (MRC) – Leading science for better health »
Showing 7 results.
Items per Page 25
of 1